Synageva BioPharma Corp.
Description Synageva BioPharma Corp., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and unmet medical needs. Its lead program, sebelipase alfa, a recombinant form of human lysosomal acid lipase (LAL) is under Phase III clinical trials for the treatment of early and late onset LAL Deficiency. The company also has various other protein therapeutic programs for rare diseases in various stages of preclinical development, including enzyme replacement therapies for other lysosomal storage disorders, as well as programs for rare life-threatening conditions. Synageva BioPharma Corp. was founded in 1996 and is headquartered in Lexington, Massachusetts. To view the detailed information, you need to SUBSCRIBE with us. |
 |